Drugs / ALTO-300
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05922878 | Jun 2023 → Dec 2026 expected | major depressive disorder | Alto Neuroscience | Recruiting | No outcome recorded |
| Phase 2 | NCT05157945 | Feb 2022 → Apr 2023 | major depressive disorder | Alto Neuroscience | Completed | No outcome recorded |
| Phase 2 | NCT05118750 | Dec 2021 → May 2023 | major depressive disorder | Alto Neuroscience | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTO-300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05118750 ↗ |
| Route | Oral | “oral (PO)” NCT05118750 ↗ |